Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2023 Nice Insight Reports
Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking
Monoclonal Antibody & Recombinant Protein: 2023 Market Analysis, CDMO Pricing and Benchmarking
mRNA Vaccines & Therapeutics: 2023 Market Analysis, CDMO Pricing and Benchmarking
Sterile Drug Product: 2023 Market Analysis, CDMO Pricing and Benchmarking
Active Pharmaceutical Ingredients: 2023 Market Analysis, CDMO Pricing and Benchmarking
Antibody Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking
Contract Research Organizations: 2023 Market Analysis, Pricing and Benchmarking
Oral Solid Dosage: 2023 Market Analysis, CDMO Pricing and Benchmarking
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
WuXi Biologics
40 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
PAO-06-022--RT-01
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
O-06-022--RT-01
Leadership
Q: What’s the key to being a leader in the industry?
PAO-03-022-RT-02
Milestones
Q: What important company milestone do you anticipate reaching in 2022?
PAO-03-022-RT-01
Facility
WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland
PR-M03-20-NI-019
Coronavirus
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19
PR-M02-20-NI-033
Clinical Results
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
PR-M02-20-NI-032
Coronavirus
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
PR-M01-20-NI-041
M&A
Wuxi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
PR-M01-20-NI-025
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
Drug Development
WuXi Biologics Congratulates Tychan on the World’s First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
PR-M11-19-NI-018
Expansion
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
PR-M06-19-NI-054
Vaccine
WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract
PR-M05-19-NI-070
Strategic Partnership
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs
PR-M04-19-NI-065
GMP
WuXi Biologics Receives EMA GMP Certificates
PR-M03-19-NI-061
Finance
WuXi Biologics Continues to Deliver Record Results
PR-M03-19-NI-052
Immuno-Oncology
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
PR-M02-19-NI-067
Strategic Collaborations
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
PR-M12-18-NI-053
Partnership
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies
PR-M12-18-NI-003
Facility
WuXi Biologics Breaks Ground on Innovation Center in China
PAO-M11-18-NI-026
Announcement
WuXi Biologics' Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting
PR-M11-18-NI-046
Manufacturing
WuXi Biologics Announced Successful Completion of the First cGMP Run in MFG3
PR-M07-18-NI-090
Investment
Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
PR-M06-18-NI-098
Strategic Partnership
WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership
PR-M06-18-NI-004
1
2
»
